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Abstract
Background: Chronic liver diseases can interfere with hepatic metabolism of lipoproteins, apolipoproteins. Hepatitis
B virus (HBV) is a major etiological agent causing acute and chronic liver diseases. Apolipoprotein M (ApoM) is a high-
density lipoprotein (HDL) apolipoprotein and exclusively expressed in the liver parenchyma cells and in the tubular
cells of the kidney. This study was to determine the correlation between HBV infection and ApoM expression.
Materials and methods: Serum ApoM levels in patients with HBV infection and in healthy individuals were
measured by ELISA, ApoM mRNA expression were determined by RT-PCR, and the expression of S and E proteins
of HBV, as well as the synthesis of viral DNA were measured by ELISA and real-time PCR.
Results: The levels of serum ApoM was significantly elevated in patients as compared to healthy individuals (P < 0.001),
ApoM promoter activity, mRNA and protein expression were all stimulated in cells transfected with infectious HBV
clone. In addition, ApoM decreases the expression of S and E proteins of HBV and the synthesis of viral DNA.
Conclusion: Raised ApoM levels in HBV infection may in turn suppress HBV replication, one of the protective
mechanisms of nature.
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Introduction
Chronic hepatitis B virus infections are a worldwide pub-
lic health burden. It is estimated over 400 million people
to date are persistently infected and these chronic infec-
tions may progress to liver damage with cirrhosis and
hepatocellular carcinoma [1-4]. HBV infection is gener-
ally considered to be noncytopathic, as chronic viremia is
not accompanied by signs of hepatocyte damage. Instead,
considerable evidence points to an important immune
and inflammatory contribution to liver dysfunction[5-8].
Apolipoprotein M (apoM) is a recently discovered 25
kDa protein, which is mainly associated with high den-
sity lipoproteins (HDL) and a minor part is present in
triglyceride-rich lipoprotein (TGRLP) and low density
lipoprotein (LDL), it is structurally related to the lipoca-
lin family[9-11]. However, the precise physiological
functions of apoM are poorly understood at present.
As the liver is the key organ for the metabolism of
lipids, lipoproteins and apolipoproteins, it is possible that
the replication of HBV or expression of viral gene pro-
ducts affects hepatocellular function at the molecular
level. For example, HBx can activate a number of cellular
genes[12-14]. It may be hypothesized that the capacity of
hepatocytes for apoM production could be changed
when HBV infection occurs.
In our present work we have compared the expression
of apoM among the serum of patients infected with HBV
and healthy individuals. We have also tried to find out
the mechanism that HBV effects ApoM production in
cells and the roles of ApoM in the expression of HBs and
HBe proteins of HBV and in the production of core-asso-
ciated DNA of HBV were determined. We found that
ApoM levels rise during the viral infection and that over
expression of ApoM suppresses HBV replication.
Materials and methods
Subjects
One hundred and 126 chronic HBV-infected patients
were enrolled in the study. The diagnosis of chronic
* Correspondence: zhouxjyk@sina.com.cn
† Contributed equally
1Center for Gene Diagnosis, Zhongnan Hospital, Wuhan University, Wuhan,
430071, P.R. China
Full list of author information is available at the end of the article
Gu et al. Lipids in Health and Disease 2011, 10:154
http://www.lipidworld.com/content/10/1/154
© 2011 Gu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.hepatitis B was confirmed by the serological examina-
tion of HBsAg and the persistence of abnormal alanine
aminotransferase activity for more than six months. We
excluded patients who had any other types of liver
damage such as autoimmune hepatitis, alcoholic liver
disease, and Wilson’s disease. The healthy control popu-
lation consisted of 118 healthy unrelated individuals
who were negative for HBsAg, anti-HBs and anti-HBc.
The local ethics committee approved the study protocol
and informed consents were obtained from all partici-
pating individuals.
Cell cultures
Two human hepatocellular carcinoma cell lines HepG2
and HepG2.2.15 were grown in 1640 medium (Gib-
coBRL, USA) with 100 units/ml penicillin, 100 μg/ml
streptomycin, and 10% heat-inactivated fetal bovine
serum. Cells were grown at 37°C in a 5% CO2 incubator.
Plasmid construction
HBV infectious clone pBlueks-HBV1.3 was constructed
previously [15]. ApoM promoter was amplified from
human genomic DNA using the following primers: 5’
CATGGTACCATAAATTTATCAAGCTAGGTGT 3’
(sense), 5’ TACACGCGTCTTTCAGCTCCCTTGCG
TTCG 3’ (antisense), and then cloned into pGL3-Basic
vector to generate ApoM promoter and Luciferase gene
fusion plasmid(pAPOM-Luc). To create ApoM -encoding
vector, the ApoM gene was amplified from HepG2 using
the following primers: 5’ TATGGATCCATGTTCCAC-
CAAATTTGGGCA 3’ (sense), 5’ GCCAAGCTTTCAGT-
TATTGGACAGCTCACA 3’ (antisense), and then cloned
into pCMV-tag2B vector(Stratagene) to generate Flag2B-
ApoM, in which ApoM protein was tagged by FLAG.
Luciferase activity assay
HepG2 cells were seeded at density of 4.0 × 106 cells per
24-well plate or 6-well plate and grown to confluence
reaching about 80%. pBluesk-HBV and pAPOM-Luc
were co-transfected into the HepG2 cells using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA) according to the
protocol provided by the manufacturer. Cells were
serum-starved for 24 h before being harvested. Firefly
and Renilla luciferase activities were measured as pre-
viously described[16]. Assays were performed in triplicate
and expressed as means ± s.d. relative to vector control
as a as 100(RLU) or luciferase activity (LUC).
Semiquantitative RT-PCR analysis
T o t a lR N Aw a si s o l a t e df r o mH e p G 2a n dH e p G 2 . 2 . 1 5
cells using Trizol reagent (Invitrogen, Carlsbad, CA) and
reverse-transcribed with oligo (dT)18 primer. PCR reaction
was performed in 25 μl solution with the gene-specific pri-
mers (20 μM) described as follows: ApoM sense: 5’-
GCTCCCTGATGTTTCCCTGAC-3’; APOM anti-sense:
5’-CACGGCCCGAGATAAGACG-3’; b-actin served as an
endogenous control using primers described previously
[17].
ELISA for ApoM measurement
ApoM levels in the culture media and serum were mea-
sured by sandwich ELISA based on two monoclonal
antibodies, M42 and M58 which was used to quantify
apoM, as described previously [18-20]. Each sample was
tested in duplicate and the concentrations were deter-
mined from the standard curve (Figure 1).
Assay for HBV protein expression
Forty-eight hours after infection, the level of HBs and
HBe proteins in cell culture media was determined by
enzyme-linked immunosorbent assay (ELISA) using
HBV S antigen and HBV E antigen diagnostic kit
(Shanghai KeHua Biotech Co. Ltd.), respectively.
Analysis of HBV DNA by real-time PCR
To determine the effect of ApoM on HBV replication,
intracellular core-associated DNA of HBV was extracted
as described previously [21]. Briefly, cells were lysed and
centrifuged at 25°C, and then magnesium chloride was
added to the supernatant. DNA not protected by HBV
core was digested with deoxyribonuclease (DNase I).
After inactivating the DNase I, cell lysate was treated
with proteinase-K and extracted with phenol/chloro-
form. Core-associated HBV DNA was recovered by
ethanol precipitation and quantified by real-time PCR as
described by the manufacturer (PG Biotech, Shenzhen,
China). The HBV DNA in the supernatants was also
quantified following the procedure provided by the
manufacturer (PG Biotech, Shenzhen, China). PCR was
c a r r i e do u ta n da n a l y z e db yaP EG e n eA m p7 7 0 0
(Perkin-Elmer).
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Figure 1 Standard curve of ApoM protein was determined with
two monoclonal antibodies, M42 and M58 by antigen capture
ELISA. Results were mean values from three separate plates run
under same conditions.
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All statistical analyses were performed by SPSS 13.0 for
windows (SPSS, Inc., Chicago). Results are presented as
means ± SD. Group means were compared using the
Student’s t-test and Analysis of Variance (ANOVA). A P
values of < 0.05 was regarded as statistically significant.
Results
Elevated apoM levels among chronic HBV infected
patients
We measured apoM concentrations in the sera of 126
HBV-infected patients and 118 healthy individuals. As
shown in Figure 2, the average ApoM concentration was
significantly elevated in these patients’ sera compared to
that of the control group (0.98 ± 0.10 μmol/L versus
0.77 ± 0.08 μmol/L; P ≤ 0.001). ApoM levels were 27
percent higher in the patients’ sera as compared to the
healthy individuals (Figure 1).
HBV enhances the ApoM promoter activity, the
transcription of ApoM mRNA and its protein expression
To determine the effects of HBV infection on ApoM
expression, we measured the luciferase values by co-
transfecting the reporter plasmid pAPOM-Luc and the
infectious clone pBlueks-HBV1.3 or pBlueks (vector
control) in order to evaluate the ApoM promoter activ-
ity in HepG2 cells. Results showed that ApoM promoter
activity was raised by more than five folds (895 ± 37.8
RUL/μg vs 162 ± 15.6 RUL/μg) (Figure 3A). These
results demonstrated that HBV stimulated the activities
of ApoM promoter. To examine the role of HBV on the
activation of ApoM mRNA, we performed semi-quanti-
tative RT-PCR. Total mRNA were extracted from
HepG2 cells transfected with pBlueks-HBV1.3 or
pBlueks. RT-PCR results showed that the levels of
*
Figure 2 Serum ApoM levels in patients and healthy
individuals. Serum ApoM levels were measured in 126 HBV-
infected patients and 118 healthy individuals by ELISA. * P ≤ 0.001.
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Figure 3 Effects of HBV on ApoM expression in transfected
cells. (A) Effect of HBV on ApoM promoter activity. HepG2 cells
were co-transfected with pGL3-ApoM-Luc and pBlueks-HBV1.3.
PBlueks was used as vector control. Luciferase activities were
determined and analyzed. (B) Effects of HBV on ApoM mRNA
expression. HepG2 cells were transfected with pBlueks-HBV1.3 or
pBlueks. ApoM mRNA was determined by semi-quantitative RT-PCR
using primers specific to each of the genes, respectively. (D) Effects
of HBV on ApoM protein expression. HepG2 cells were transfected
with pBlueks-HBV1.3 or pBlueks. The levels of ApoM protein were
determined by ELISA.
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cells transfected with pBlueks-HBV1.3 as compared to
pBlueks. The total mRNA was balanced by using beta-
actin as an internal control (Figure 3B). These results
suggest that HBV enhances ApoM mRNA expression.
Comparable results were validated by ApoM protein
expression in the presence or absence of HBV. ELISA
results revealed that ApoM protein level was higher in
HepG2 cells transfected with pBlueks-HBV1.3 than
that with vector control (0.79 ± 0.21 μmol/L vs 0.58 ±
0.13 μmol/L) (Figure 3C). These results demonstrated
that HBV stimulates ApoM protein expression.
Raised levels of ApoM suppress HBV protein expression
and viral replication
The increased levels of APOM in response to HBV
s h o u l ds o m e w a ya f f e c tt h ev i r u s .T oe v a l u a t et h ee f f e c t s
of ApoM on HBV gene expression and viral replication,
HepG2.2.15 were transfected with Flag2B-ApoM or an
empty vector control. Forty-eight hours post-infection,
the levels S protein (HBs) and E protein (HBe) of HBV in
the supernatant of cell cultures were measured by ELISA.
Results showed that the level of HBs and HBe exhibited
more than 3 folds decrease in ApoM over-expressing
cells (Figure 4A and 4B), These results demonstrated that
the expression of HBs and HBe proteins of HBV was sup-
p r e s s e db yA p o M .T h ea b o v er e s u l t sa l s oi m p l i e dt h a t
ApoM has a inhibitory effect on HBV replication. To
confirm such effect, the levels of intracellular core-asso-
ciated DNA of HBV were determined by real-time PCR.
Results showed that the level of HBV DNA was
decreased more than 3 folds in ApoM over-expressing
cells (Figure 4C). These results clearly indicated that
ApoM can inhibit HBV replication.
Discussion
HBV is not directly cytopathic but its interaction with
the host immune system creates opportunity for HBV
DNA integration into the host genome. HBV causes
l i v e ri n j u r yb ya ni m m u n er e sponse against the virus-
infected liver cells[22,23].
ApoM was originally found in chylomicrons and is
found in all major lipoprotein classes [9], it is highly
hydrophobic and must co-circulate with lipoprotein par-
ticles in the blood stream[24,25]. In this study we pre-
sent evidence that HBV promotes ApoM production
both in vivo and in vitro.
A 27 percent increase in ApoM levels in HBV patients
as compared to healthy individuals was observed. It is
well known that chronic liver diseases can interfere with
hepatic metabolism of lipids, lipoproteins or apolipopro-
teins, as most plasma endogenous lipids and lipopro-
teins are synthesized by the liver, which depends on the
integrity of liver cell function. As apoM is exclusively
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Figure 4 Determination of the roles of ApoM in HBV gene
expression and viral DNA replication. HepG2.2.15 cells were
infected with Flag2B-ApoM and harvested 48 h post-infection. The
expression of S protein (A) and E protein (B) of HBV in the
supernatant of cell culture was measured by ELISA using diagnostic
kits for HBV. The production of core-associated DNA (C) of HBV was
determined by real-time PCR. Results represent means of three
independent experiments, with derived standard errors shown.
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[26,27], it could be hypothesized that the normal hepatic
physiological processes are necessary for hepatic apoM
production, and in cases of HBV infection, there may be
interference in the apoM synthesis. It has been reported
that the plasma apoM levels were higher in the patients
suffered from HCC and other chronic liver diseases
than in normal subjects[28,29]. Our result is in line with
earlier results from experiment based on semiquantita-
tively determined by both dot-blotting and western blot-
ting analysis[29]. However, we didn’tf i n da n y
correlation between HBV viral load and ApoM levels.
Initial rise in HBV serum ApoM prompted us to
investigate further. Our in vitro results showed that
there was a six fold increase in the promoter activity of
the ApoM in the presence of infections HBV clone.
This increase in ApoM promoter activity was substan-
tiated by increased ApoM mRNA level and protein
expression. Many intracellular pathways are activated by
HBV infection, which may positively regulate ApoM.
The cellular signaling pathways involved in the process
are currently under investigation.
A rise in the ApoM protein expression in response to
viral infection poses a potential query that how this would
affect the contributory viral agent. To respond to this
issue, we further studied the effects of ApoM on HBV
gene expression and viral replication in cell culture models
by using HepG2.2.1.5 cell line, which carries several copies
of the HBV genome on its chromosome. The effects of
ApoM on HBV gene expression and viral replication were
studied thoroughly by the analyzing the levels of viral pro-
tein production through enzyme-linked immunosorbent
assays and the levels of viral RNA expression by semi-
quantitated RT-PCR analysis. All results indicated that
ApoM had significant inhibitory effects on viral mRNA
expression, viral protein production. Thus, we provided
evidence that ApoM is an important mediator of HBV
r e p l i c a t i o na n dm a yb eap o t e n t i a lt h e r a p e u t i ca g e n tf o r
HBV infection.
In a nutshell, our present work shows that raised
ApoM levels in HBV infection may in turn hamper
HBV replication in vitro, one of the protective mechan-
isms of nature during HBV infection. However, whether
apoM in vivo can protect against the HBV infection is
still unknown, experiments showing the dose response
effect of HBV infection in apoM genemodified mice
were to be done.
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